Concept Architecture
Concept
Theoretically, Quality-Adjusted Time Without Symptoms is a preference-based health outcome measure that quantifies the duration of time spent free from disease symptoms after adjustment for health-related quality of life. It extends the principles of the Quality-Adjusted Life Year (QALY) by focusing specifically on symptom-free survival rather than total survival. The concept exists to capture both the length and quality of symptom-free time, particularly in conditions where treatment effectiveness is reflected by delaying symptoms while maintaining quality of life.
Mathematically, quality-adjusted time without symptoms is calculated by weighting symptom-free survival time by the utility associated with the corresponding health state. Where utility varies during symptom-free survival, the measure is estimated using the area-under-the-curve approach by integrating utility over the symptom-free period. The resulting value represents the equivalent duration of symptom-free life in perfect health.
In practice, quality-adjusted time without symptoms is estimated by combining symptom-free survival data with utility values obtained from preference-based instruments such as the EQ-5D, HUI or SF-6D. The measure is commonly applied in oncology, chronic disease management and clinical trials where prolonging symptom-free survival is an important treatment objective. Health economists use the measure to compare interventions when symptom control is a principal determinant of patient benefit.
Purpose
Used to quantify quality-adjusted symptom-free survival, evaluate interventions that delay symptom onset, compare treatment effectiveness, and support cost-utility analyses where symptom-free time is a key clinical outcome.
Mathematical Formulae
Primary Formula
QATWS = ?????? u??t
where:
- QATWS = quality-adjusted time without symptoms
- u? = health utility during symptom-free period t
- ?t = duration of the period
- T? = total symptom-free survival time
Supporting Formulae
Continuous formulation:
QATWS = ???? u(t) dt
Discounted formulation:
QATWS = ?????? (u??t) / (1 + r)?
where:
- r = annual discount rate
Related Mathematical Methods
- Area-under-the-curve estimation
- Health utility measurement
- Survival analysis
- Cost-utility analysis
- Decision-analytic modelling
- Discounting
Example
A patient remains symptom-free for three years following treatment. Utility values during these years are estimated as 0.95, 0.90 and 0.85.
QATWS = (0.95 ? 1) + (0.90 ? 1) + (0.85 ? 1)
QATWS = 2.70
The intervention therefore provides 2.70 quality-adjusted symptom-free years before symptoms develop.
Excel Implementation
| Function | Example Formula | Health Economics Application |
|---|---|---|
| SUMPRODUCT | =SUMPRODUCT(B2:B4,C2:C4) | Calculate quality-adjusted symptom-free time by multiplying utility values by symptom-free intervals |
| SUM | =SUM(D2:D4) | Sum quality-adjusted symptom-free intervals |
| NPV | =NPV(0.035,D2:D20) | Discount future quality-adjusted symptom-free time |
| IF | =IF(B2>1,""Invalid"",B2) | Validate utility values before calculation |
VBA (Optional)
Automate calculation of quality-adjusted symptom-free survival for patient cohorts using longitudinal utility and survival data.
Sources
- Gelber RD, Goldhirsch A, Cole BF. Quality-adjusted survival (Q-TWiST) and related quality-adjusted survival methods in oncology.
- Revicki DA, Feeny D, Hunt TL, Cole BF. Analyzing oncology clinical trial data using quality-adjusted survival methods.
- Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press.
- Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. Oxford University Press.
- NICE. Health Technology Evaluation Manual.
Related Concepts (3)
Library
Publications
1
Measuring and Valuing Health Benefits for Economic Evaluation — Brazier, Ratcliffe, Salomon & Tsuchiya, 2nd Edition ed., 2017 (Oxford University Press)
The comprehensive text on the measurement and valuation of health benefits for economic evaluation — defining health, valuation techniques (time trade-off, standard gamble), whose values to use, preference-based measures (EQ-5D, SF-6D), and the construction of QALYs.
BookView source →
Frequently Asked Questions (6)
What is quality-adjusted time without symptoms and toxicity?
An oncology outcome measure, Q-TWiST, dividing survival into phases, such as toxicity, symptom-free time, and time after relapse, each weighted by quality of life.
Source: Gelber et al. 1989
How does Q-TWiST differ from a standard QALY analysis?
Q-TWiST applies the quality-adjusting idea but splits survival into clinically meaningful phases and weights each rather than assigning a single utility to the whole. It separates time spent with treatment toxicity, time free of symptoms, and time after relapse, then attaches a quality weight to each phase and adds them. This makes the trade-off between the harms of treatment and the benefit of symptom-free time explicit, which a single averaged utility would obscure. Gelber and colleagues (1989) set out the method.
Source: Gelber et al. 1989
How does Q-TWiST work?
Q-TWiST works by partitioning a patient's survival into clinically meaningful phases: a period affected by treatment toxicity, a period free of symptoms and toxicity, and a period after relapse or progression. Each phase is assigned a quality-of-life weight reflecting how that time is valued, and the weighted durations are summed to give the quality-adjusted survival. Comparing treatments on this combined measure shows whether a gain in survival is worth the toxicity or relapse time it entails, rather than counting all survival equally.
Source: Gelber et al. 1989
Why was Q-TWiST developed for oncology?
Q-TWiST was developed for oncology because cancer treatments often extend survival at the cost of significant toxicity, and relapse periods differ in quality from symptom-free time, so counting all survival equally can mislead. A more toxic treatment that lengthens life may offer little net benefit once the quality of the added time is considered. By weighting phases of toxicity, symptom-free time, and relapse differently, Q-TWiST captures these trade-offs, giving a measure suited to comparing cancer treatments on quality-adjusted rather than raw survival.
Source: Gelber et al. 1989
What are the phases in the Q-TWiST framework?
The Q-TWiST framework typically divides survival into three phases: a period with toxicity from treatment, often weighted below full value; the time without symptoms and toxicity, the symptom-free and toxicity-free period usually weighted highest; and the time after relapse or progression, weighted according to its reduced quality. Each phase's duration is multiplied by its quality weight and the results summed. The phases reflect the clinical course of cancer treatment, allowing the quality of different periods of survival to be valued separately.
Source: Gelber et al. 1989
What are the limitations of Q-TWiST?
Q-TWiST has limitations. The quality weights for each phase are value judgements that affect the result, and conclusions can depend on the weights chosen, so sensitivity analysis over them is needed. Dividing survival into phases requires clinical definitions of toxicity and relapse that may vary. Like other quality-adjusted measures, it combines length and quality into one figure that can obscure their separate contributions. It is also specific to the oncology setting it was designed for, limiting its use elsewhere.
Source: Gelber et al. 1989
Trust Record
Verified by Dr Darrin Baines
British health economist
Professional identity: darrinbaines.org
Verification date: 17 Sep 2025
Content version: 1.0.0
Canonical Identity
- Term code
- HE-EE-QALY-009
Stable URI · Machine-readable · Resolvable · CC BY 4.0